Get the Stockscreener App
14.58
0.82%
-0.12
Edgewise Therapeutics Inc stock is traded at $14.58, with a volume of 787.33K.
It is down -0.82% in the last 24 hours and up +16.64% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
See More
Previous Close:
$14.70
Open:
$14.95
24h Volume:
787.33K
Relative Volume:
0.46
Market Cap:
$1.78B
Revenue:
-
Net Income/Loss:
$-115.88M
P/E Ratio:
-9.4259
EPS:
-1.5468
Net Cash Flow:
$-104.72M
1W Performance:
-13.78%
1M Performance:
+16.64%
6M Performance:
-59.92%
1Y Performance:
-27.10%
1-Day Range:
$14.51
$15.55
1-Week Range:
$13.82
$16.91
52-Week Range:
$10.60
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
14.58 | 1.78B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by DAFNA Capital Management LLC - MarketBeat
Driehaus Capital Management LLC Decreases Stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Deerfield Management Company L.P. Series C Boosts Stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Bamco Inc. NY Makes New $1.60 Million Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Algert Global LLC Acquires 100,859 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Deep Track Capital LP Trims Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics Reports Strong Q1 2025 Progress - TipRanks
Wedbush Adjusts Price Target on Edgewise Therapeutics to $40 From $43, Maintains Outperform Rating - marketscreener.com
Edgewise Therapeutics shares fall on in-line Q1 results By Investing.com - Investing.com UK
EDGEWISE THERAPEUTICS Earnings Results: $EWTX Reports Quarterly Earnings - Nasdaq
Edgewise Therapeutics, Inc. SEC 10-Q Report - TradingView
Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire
Braidwell LP Increases Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by Baker BROS. Advisors LP - MarketBeat
Schonfeld Strategic Advisors LLC Reduces Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
Ally Bridge Group NY LLC Sells 104,519 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Acuta Capital Partners LLC Buys 24,658 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Invesco Ltd. Sells 21,341 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (EWTX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Acquired by Envestnet Asset Management Inc. - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is Novo Holdings A S's 4th Largest Position - MarketBeat
Marshall Wace LLP Has $798,000 Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Now Covered by Guggenheim - MarketBeat
Voya Investment Management LLC Lowers Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Is Edgewise Therapeutics, Inc. (EWTX) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Insider Monkey
Adage Capital Partners GP L.L.C. Purchases 218,491 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Foresite Capital Management VI LLC Buys New Stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey
First Light Asset Management LLC Invests $20.84 Million in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Why Edgewise Therapeutics Stock Popped This Week - The Globe and Mail
Edgewise Therapeutics (EWTX) Initiated at Buy by Guggenheim, Pot - GuruFocus
Edgewise a new buy at Guggenheim on two pipeline prospects - Seeking Alpha
Edgewise Therapeutics (EWTX) Receives Positive Coverage with Str - GuruFocus
Guggenheim Starts Edgewise Therapeutics With Buy Rating, $41 Price Target - marketscreener.com
79,381 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Bought by Harvest Investment Services LLC - MarketBeat
JPMorgan Chase & Co. Sells 34,071 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Russell Investments Group Ltd. Makes New $883,000 Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics' (EWTX) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Analysts Set Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Price Target at $40.38 - MarketBeat
Is Edgewise Therapeutics Inc. (NASDAQ:EWTX) the Most Promising Small-Cap Stock According to Analysts? - Insider Monkey
Jump Financial LLC Sells 76,628 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):